Phase 2b study of intranasal pertussis vaccine candidate BPZE1 in children published in The Lancet Infectious Diseases.

ILiAD Biotechnologies announced the publication of results from its Phase 2b SUPER (Stand Up to Pertussis) clinical trial in The Lancet Infectious Diseases. The randomized, double-blind, placebo- and active-comparator-controlled study demonstrated that BPZE1, a live attenuated intranasal pertussis vaccine, induced robust nasal mucosal immune responses and exhibited a favorable safety profile in healthy children aged 6 through 17 years. This research supports the continued development of BPZE1 as a potential next-generation vaccine to prevent pertussis infection and transmission.